Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants

Neonatology

Volumn 105, Issue 1, 2013, Pages 46-54

  Lago, Paola ^a   Salvadori, Sabrina ^a   Opocher, Francesca ^a   Ricato, Silvia ^a   Chiandetti, Lino ^a   Frigo, Anna Chiara ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Continuous infusion; Efficacy; Ibuprofen; Patent ductus arteriosus; Preterm infant; Safety

Indexed keywords

CREATININE; IBUPROFEN;

ARTICLE; BLEEDING; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROLYTE INTAKE; FEMALE; FLUID INTAKE; GASTROINTESTINAL HEMORRHAGE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; INTESTINE PERFORATION; LEUKOMALACIA; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; NEWBORN MORBIDITY; NEWBORN MORTALITY; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; SIDE EFFECT; URINE VOLUME; VERY LOW BIRTH WEIGHT;

DOUBLE-BLIND METHOD; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; ENTEROCOLITIS, NECROTIZING; FEMALE; HEMODYNAMICS; HUMANS; IBUPROFEN; INCIDENCE; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84898486317     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000355679     Document Type: Article

References (26)

1. Vermont Oxford Network: Vermont Oxford Network Annual Report. Burlington, Vermont Oxford Network, 2010, Section 2, Table 2.5.
2. Clyman RI: The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol 2013; 37: 102-107.
3. Noori S: Patent ductus arteriosus in the preterm infant: to treat or not to treat. J Perinatol 2010; 30:S31-S37.
4. Kabra NS, Schmidt SB, Roberts RS, Doyle LW, Papile L, Fanaroff A: Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in preterms. J Pediatr 2007; 150: 229-234.
5. Hammerman C, Bin-Nur A, Kaplan M: Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew. Semin Perinatol 2012; 36: 130-138.
6. Van Overmeire B, Smets K, Lecoutere D, Van De Broek H, Weyler J, De Groote K, Langhendries JP: A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674-681.
7. Lago P, Bettiol T, Salvadori S, Pitassi I, Vinello A, Chiandetti L, Saia OS: Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomized controlled trial. Eur J Pediatr 2002; 161: 202-207.
8. Ohlsson A, Walia R, Shah SS: Ibuprofen for the treatment of ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2013; 4:CD003481.
9. Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S: An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetics and pharmacodynamic study. Br J Clin Pharmacol 2008; 65: 629-636.
10. Desfrere L, Zohart S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, Rey E, Treluyer JM: Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30: 121-132.
11. Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, Ciuti R, Bandinelli A, Martano C, Murru P, Messner H, Schena F, Mosca F: High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled trial. Clin Pharmacol Ther 2012; 91: 590-596.
12. Neumann R, Schulzke SM, Buhrer G: Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012; 102: 9-15.
13. Lago P, Salvadori S, Ziggiotto E, Chiandetti L: Ibuprofen for PDA treatment: bolus vs constant infusion: a pilot study. Acta Paediatr 2007; 96: 237.
14. McNamara PJ, Sehgal A: Towards rational management of patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92:F424-F427.
15. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L: Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005; 90:F419-F422.
16. Kluckow M, Evans N: Superior vena cava flow in newborn infants: a novel marker of systemic blood flow. Arch Dis Child Fetal Neonatal Ed 2000; 82:F182-F187.
17. Zubrow AB, Hulman S, Kushner H, Falkner B: Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15: 470-479.
18. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1987; 34: 571-590.
19. Walsh M, Kliegmann R: Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33: 179-201.
20. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T: Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in vitro correlation and inducibility. Pharmacogenetics 1997; 7: 441-452.
21. Aranda JV, Varvarigou A, Beharry K, Bansal R, Bardin R, Modanlou H, Papageorgiou A, Chemtob S: Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997; 86: 289-293.
22. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001; 53: 1679-1685.
23. Van Overmeire B, Touw D, Schepens PJC, Kearns GL, van der Anker JN: Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 2001; 70: 336-343.
24. Guignard JP: The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002; 26: 398-405.
25. Vieux R, Desanders R, Boubred F, Semama D, Guillemin F, Buchweiller MC, Fresson J, Hascoet JM: Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol 2010; 25: 267-274.
26. Allegaert K, Cossey V, Langhendries JP, Naulaers G, Vanhole C, Devlieger H, Van Overmeire B: Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 2004; 86: 207-211.